The in vitro susceptibilities of 34 to 73 clinical isolates of Clostridium difficile to 24 antimicrobial agents, including 18 P-lactams, 4 fluoroquinolones, clindamycin, and metronidazole were examined. Metronidazole was the most active (MIC for 90% of the isolates [MIC901, 0.5 ,Lg/ml), followed by the carbapenems (Sch 34343, 4 ,Ig/ml; imipenem, 8 ,ug/ml) and the antipseudomonas penicillins (piperacillin, 8 ,Ig/ml; ticarcillin, 32 ,Lg/ml; carbenicillin, 32 ,Ig/ml). A monobactam (aztreonam) and most cephalosporins were either highly inactive (cefoxitin, cefuroxime, cefotiam, cefsulodin, ceftizoxime, cefbuperazone, and cefotaxime), with an MIC90 of >128 ,ug/ml, or moderately inactive (ceftriaxone, cefmenoxime, cefoperazone, ceftazidime, and moxalactam), with an MIC90 of .32 ,ug/ml. Clindamycin (MIC90, 32 ,fg/ml) and the fluoroquinolones (ciprofloxacin, 8 tig/ml; A-56619, 8 ,ug/ml; A-56620, 8 ,ug/ml; norfloxacin, 32 ,ug/ml) were only variably active. These in vitro data per se may not necessarily predict the relative risks for C. difficie-associated diarrhea or colitis during therapy with these agents. However, these data, in concert with knowledge of drug bioavailability in feces and the broad-spectrum antimicrobial activity on the resident bowel flora, may provide additional insight into the mechanisms and predictability of this complication with these agents. Careful monitoring for the emergence of C. difficile and fecal cytotoxin and for diarrhea during therapy with these agents is clearly indicated.
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Recent studies strongly implicate Clostridium difficile as a major cause of antibiotic-induced pseudomembranous colitis (4, 5) . Although ampicillin, clindamycin, and cephalosporins have been the agents most frequently reported, nearly all antibacterial agents in clinical use have been implicated (3, 9) . The in vitro susceptibilities of C. difficile to newgeneration ,B-lactams and quinolone antibiotics have not been extensively studied. Although agents with excellent activity in vitro against C. difficile (e.g., ampicillin and metronidazole) are not necessarily exempt from the risk of C. difficile-associated diarrhea, agents with broad-spectrum activity but to which C. difficile is resistant appear to be particularly predisposed to this complication (2, 6, 11). We have, therefore, examined the in vitro susceptibilities of 73 clinical isolates of C. difficile to 18 ,B-lactam and 4 quinolone antibiotics with broad-spectrum activity. These included antipseudomonas penicillins (carbenicillin, ticarcillin, and piperacillin), carbapenems (imipenem, and Sch 34343), a monobactam (aztreonam), cephamycins (cefoxitin and cefbuperazone), aminothiazolyloximino and related cephalosporins (cefuroxime, cefotiam, cefmenoxime, ceftriaxone, ceftizoxime, cefotaxime, and ceftazidime), miscellaneous cephalosporins (cefoperazone, cefsulodin, and moxalactam), and fluoroquinolones (norfloxacin, ciprofloxacin, A-56619, and A-56620). Susceptibilities to clindamycin and metronidazole were also tested for comparison. All C. difficile strains were fecal isolates from inpatients at Vancouver General Hospital clinically suspected of having antibiotic-associated diarrhea. All isolates were determined to be toxigenic in vitro by a cytotoxin assay with human foreskin fibroblasts in a microtiter tissue culture system (15) . The isolates were stored in 20% skim milk and frozen at -70°C until ready for susceptibility testing. The MICs for the organisms were determined by an agar dilution method with Wilkins-Chalgren medium and inocula of 105 CFU as previously described (14) . Three reference strains (Bacteroides fragilis ATCC 25285, B. thetaiotaomicron ATCC 29741, and C. perfringens ATCC 13124) were included on each agar plate to assess reproducibility. The 6 control subjects receiving no antibiotics. These authors (1) concluded that antibiotics with broad-spectrum activity against both aerobic and anaerobic flora of the colon were particularly at risk for the emergence of C. difficile after drug administration.
The fluoroquinolones, including the aryl derivatives (A-56619 and A-56620), were also relatively inactive in the present study. However, these agents have excellent bioavailability in feces (10) 
